Clinical Trials

A clinical trial sponsored by EcoNugenics evaluated the safety and efficacy of modified citrus pectin in patients with prostatic neoplasms. This completed Phase 2 study focused primarily on prostate-specific antigen kinetics to determine the agent's impact on disease progression and biochemical dynamics in prostate cancer. Ultimately, the trial provides preliminary clinical evidence regarding the therapeutic utility and safety profile of pectin interventions within oncological care.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01681823 Completed
Prostatic Neoplasms
EcoNugenics
2013-06 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Pectin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a plant-derived heteropolysaccharide, pectin directly binds to bacterial toxins, mucosal irritants, and cell-surface ligands, thereby neutralizing harmful biochemical interactions and serving as a bioactive matrix for cellular adsorption. This molecular binding capability relieves mucosal irritation and modulates cellular signaling, providing a therapeutic rationale for its clinical evaluation in controlling tumor kinetics and disease progression in prostatic neoplasms.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.